预约演示
Novartis hits the cGAS, taking option to buy IFM unit for $90M upfront
临床1期并购引进/卖出
Novartis has gained full rights to a portfolio of STING antagonists.
Novartis is stepping on the cGAS. Three years afteSTING antagonistsion on an IFM Therapeutics subsidiary, the Swiss drugmaker has accelerated into the deal and paid $90 million upfront for small molecules that inhibit the cGAS-STING pathway.
Novartisers have uncovered the role the cGAS-STING pathway plays in the mediaIFM Therapeuticstion in response to infection, cellular stress and tissue damage over the past decade or so, spurring interest in targeting the acGAStSTINGat autoimmune and degenerative diseases. Novartis threw its weight behind the push by agreeing to fund research at an IFM subsidiary, IFM Due, in 2019.
Having bankrolled the preclinical researcGAS-STINGis has seen enough promise to warrainflammationore money into tinfectionm. The drugmaker has paid $90 million upfront and committed up to $745 million in milestone payments to acquire Iautoimmune and degenerative diseasesNovartis
In return, Novartis has gained full rights tNovartisfolio of STING antagonists with potential applications in the treatment of a range of diseases characterized by excessive interferon and other pro-inflammatory cytokine signaling. ThIFM Dueing's release lacks details of the status of the molecules, but the original plan was for Novartis to fund IFM Due through late-stage preclinical development of the lead program.
Drug develoNovartis attacking the cGAS-STING pathway from mulSTING antagonists approach is to inhibit cGAS, an enzyme that activates STING. Ventus Therapeutics recently began a phase 1 clinical trial of a cGAS inhibitor, while Nimbus Therapeutics has a discovery-stage cGAS program in its pipeline. Other groups, including Bayer anNovartisis, have inked deals for antagonists of STING.
Novartis’ decision to take up its cGAS-STINGIFM Due comes four years after it paid $310 million to buycGASther of the biotech’s subsiSTINGesVentus Therapeuticsgave Novartis control of the clinical and preccGAS inhibitorcGAScal NLRP3 antagoniNimbus Therapeuticsat IFM Tre. IFM sold prcGASnical STING and NLRP3 agonist programs to Bristol Bayer SquiNovartis17.STING
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。